🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our CEO and Co-Founder, Pete Smith, will be joining a panel hosted by Rami Rahal, MPM BioImpact, to discuss the exciting progress we are making in “Drugging the Undruggable/Transcription Factors” at the American Society for Cancer Research Annual Meeting. See you there! #AACR25

Today we announced the appointment of Linda Bain to our Board of Directors. Ms. Bain, who brings more than 20 years of financial, operational and executive leadership launching and growing life sciences companies, is a Venture Partner at Altas Venture. bit.ly/4lvZFTN

The Remix Women’s Group recently discussed The Immortal Life of Henrietta Lacks, a powerful story about medical ethics and the woman behind the HeLa cells. Thank you to Christoph Lengauer, CSO at Curie.Bio, for sharing his personal experiences from the story.

Today, on World Acute Myeloid Leukemia day, we reflect on the progress that has been made & the continued importance of research for effective treatment options. Our clinical trial REM-422 in patients with AML or Higher Risk MDS is ongoing. 👉bit.ly/4jfuhH9 #KnowAML

We teamed up with Jim Ellis' Brix & Merlot for our annual Wine Trivia fundraiser—raising a glass (and funds!) for a cause near and dear to #Remixers. With sips and science on our minds, we put our brains to the test, in the name of fun, philanthropy, and #RemixingTogether. 🧠🍷

Charles Kung presenting REM-422, a first-in-class, orally available small molecule degrader of MYB mRNA at #AACR today. REM-422 induces tumor regressions in MYB-dysregulated preclinical models at well tolerated doses & is in two Phase 1 clinical trials. bit.ly/4c4FkAr

CEO Pete Smith participated in the “Drugging the Undruggable/Transcription Factors” panel at #AACR25. We're proud of Remix’s contributions in this field & hope to continue the conversation. Thank you Jonathan Chang/Leerink, the panelists & MPM BioImpact for a great discussion!

📣 Benoit Moreau, Remix’s Head of Medicinal Chemistry will be the Roundtable facilitator for the “From PROTACs to RNA-Modulated Degraders: Engineering Novel Therapeutics for Hard-to-Target Proteins” session. ➡bit.ly/3RroSRu

📣Our CSO, Dom Reynolds, will be speaking tomorrow at the 5th Workshop on Splicing Factor Mutations & RNA Biology in Cancer, bringing together leaders in the research community for collaborative discussions to advance the field and new pathways for treatments. #OncologyResearch

Preclinical data evaluating anti-tumor activity of REM-422 in xenograft models of AML selected for a poster presentation at the European Hematology Association 2025 Congress. REM-422 is a first-in-class degrader of the MYB protein in Phase 1 studies for AML and ACC. bit.ly/4mhxTuD

Hear from Dom Reynolds, our CSO, about his perspective on how Remix is tackling one of the biggest factors in being able to treat cancer and other difficult to treat diseases - undruggable proteins. bit.ly/3H5dsAX #OncologyResearch #ACC #AdenoidCysticCarcinoma #AML

This week, we hosted students from EVkids, a nonprofit that supports Boston youth, for a hands-on intro to biotech! From extracting strawberry DNA to learning how AI powers drug discovery, they explored the many career paths science has to offer. Grateful to be part of this!👨‍🔬🧬

Closing out #mentalhealthmonth, we reflect on how we create a healthier, more human workplace at Remix - staying connected as a team by focusing on our mission while recharging with things like yoga, volunteering on the Charles, and showing up in green to support the cause.

Learn more about Remix’s innovative approach to drug design. Head of Medicinal Chemistry, Benoit Moreau, will be speaking at the 2nd Structure Based Drug Design Summit Meeting & the Precision in Drug Discovery & Preclinical Summit: bit.ly/42KveRd bit.ly/3Y9k1YT

Sarah Sirin, Director & Head of Computational Chemistry, participated in Scientific Computing World’s roundtable on the data impact of working with emerging modalities, like RNA therapeutics and protein degraders. Learn more: bit.ly/3ZmPmbg

See you at BIO International next week! Heather Wasserman, Remix's CBO/COO will be onsite and looking forward to meeting with current partners and networking with new colleagues about Remix's approach to addressing the intractable drivers of disease. #OncologyResearch #BIO2025

Data presented in poster sessions at the AACR and European Hematology Association Conferences demonstrate the importance of the MYB protein as the driver of diseases like ACC and AML. Learn more about REM-422 and Remix's ongoing clinical trials: bit.ly/44qEk6D

🌈 Proud to host OUTbio Founder Ramsey Johnson for a powerful session on OUTbio’s mission to empower LGBTQ professionals and allies across the industry. At Remix, we’re committed to fostering a culture of inclusion, authenticity, and belonging, within our walls and across biotech

📣Next week, CEO, Pete Smith, will be presenting on an Oncology panel and part of a Q&A session at Evercore’s emerging Private Biotech Conference. Looking forward to discussing Remix’s approach to tackling diseases by modulating RNA processing with small molecules. #Evercore

MYB is an oncogenic transcription factor that is dysregulated in cancers like ACC, AML, and HR-MDS. REM-422 is an oral mRNA degrader that reduces MYB mRNA and protein expression, resulting in antitumor activity in MYB-dependent human tumor models. ➡️bit.ly/4kJkYQ4